Jazz Pharmaceuticals PLC $JAZZ Holdings Raised by UBS Group AG

UBS Group AG increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 472,952 shares of the specialty pharmaceutical company’s stock after buying an additional 13,485 shares during the quarter. UBS Group AG’s holdings in Jazz Pharmaceuticals were worth $80,402,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 9.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 81 shares in the last quarter. Fairbanks Capital Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 0.4% in the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after acquiring an additional 94 shares in the last quarter. Blair William & Co. IL boosted its holdings in shares of Jazz Pharmaceuticals by 5.0% in the third quarter. Blair William & Co. IL now owns 2,107 shares of the specialty pharmaceutical company’s stock valued at $278,000 after acquiring an additional 101 shares in the last quarter. Arkadios Wealth Advisors increased its stake in shares of Jazz Pharmaceuticals by 0.9% during the third quarter. Arkadios Wealth Advisors now owns 13,948 shares of the specialty pharmaceutical company’s stock valued at $1,838,000 after acquiring an additional 123 shares during the period. Finally, Geneos Wealth Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the sale, the director directly owned 7,024 shares in the company, valued at $1,348,608. This trade represents a 32.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 74,015 shares of company stock worth $14,180,486. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research analyst reports. Leerink Partners upped their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Needham & Company LLC lifted their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Truist Financial raised Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Bank of America upped their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $216.87.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $202.72 on Monday. The firm has a market cap of $12.72 billion, a PE ratio of -33.96, a P/E/G ratio of 0.35 and a beta of 0.27. Jazz Pharmaceuticals PLC has a 12 month low of $97.50 and a 12 month high of $207.48. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. The firm has a 50 day simple moving average of $189.65 and a 200 day simple moving average of $171.11.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.51 earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 20.51 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.